男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影
Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Merck to invest more in country, sharpen focus on R&D, local tie-ups

By LIU ZHIHUA | China Daily | Updated: 2024-07-30 09:30
Share
Share - WeChat
A view of Merck's booth during an expo in Shanghai last month. [Photo/China Daily]

Merck will continue to invest in China, which is not only the second-largest consumer market in the world but also has rising innovation capability, said a senior executive of the German science and technology company.

"China is a significant market for us, for looking at innovation to bring it outside China and bringing our innovation into China," said Peter Guenter, a member of the executive board and CEO of Healthcare at Merck.

"We have done a lot of investments in China. Our commitment to China is clear. We will continue to grow, and we will continue to invest in the country."

The executive is deeply impressed by the remarkable changes in China's pharmaceutical market as it has "developed incredibly over the last 10 to 20 years, transforming from a generic industry focused on small molecules to one driven by innovation".

China has become very strong in technological innovation, as reflected by its rapid progress and innovation in the field of antibody-drug conjugates, he said.

China's huge potential as a major innovation hub holds great promise for Merck to collaborate with local partners, including startups, biotech and biopharma firms, and research institutes, to drive innovation forward, said Guenter.

"At a certain point in time, China could be the country from which innovation comes, truly first. I think that's the next frontier for the Chinese R&D ecosystem, to continue being very, very good at perfecting technologies, but also going upstream to find a new molecule for a new disease."

Citing various dynamics behind China's growing innovation drive that include well-educated talent and enabling regulatory environment, the executive spoke particularly highly of the clinical development pace in China.

The speed, agility and quality of the Chinese investigators who conduct clinical trials are remarkable, he said, adding the massive number of patients with unmet medical needs also contributes to the speedy drug development pace in the country.

1 2 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 利辛县| 新晃| 保山市| 丘北县| 连云港市| 察隅县| 盐山县| 葵青区| 合肥市| 鸡泽县| 九寨沟县| 通州区| 博爱县| 都安| 池州市| 阳朔县| 道真| 清水河县| 新津县| 宜良县| 湘乡市| 佛山市| 永寿县| 获嘉县| 原平市| 敖汉旗| 饶阳县| 清新县| 五台县| 新邵县| 土默特左旗| 黄平县| 阳城县| 新源县| 沙洋县| 福鼎市| 汪清县| 苏州市| 叶城县| 镇雄县| 建始县| 连城县| 蓬安县| 芜湖县| 库车县| 房产| 松潘县| 建平县| 崇义县| 津市市| 华蓥市| 安塞县| 中江县| 红原县| 贺州市| 吴江市| 新宾| 卓尼县| 玛曲县| 武山县| 泸西县| 兴化市| 乐山市| 土默特左旗| 九龙县| 芦山县| 峨眉山市| 自贡市| 科尔| 大埔县| 淮阳县| 新蔡县| 鄂尔多斯市| 东宁县| 元谋县| 岢岚县| 岳阳县| 普定县| 黑龙江省| 海宁市| 永年县| 玛纳斯县|